Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097974 | 0.85 | POLB (0.52) | CTSLCTSBCTSSCNR2POLB | |
| SCHEMBL28502817 | 0.83 | POLB (0.51) | CNR2POLBALDH1A1MEN1KMT2A | |
| SCHEMBL28502815 | 0.83 | POLB (0.51) | CNR2POLBALDH1A1MEN1KMT2A | |
| SCHEMBL7453661 | 0.83 | CNR2 (0.54) | CTSLCTSBCTSSCNR2POLB | |
| SCHEMBL7453658 | 0.83 | CNR2 (0.54) | CTSLCTSBCTSSCNR2POLB | |
| SCHEMBL646059 | 0.81 | ALDH1A1 (0.56) | CTSLCTSBCTSSCNR2POLB | |
| SCHEMBL4156603 | 0.81 | ATM (0.65) | CTSLCTSBCTSSPOLBALDH1A1 | |
| SCHEMBL646058 | 0.81 | ALDH1A1 (0.56) | CTSLCTSBCTSSCNR2POLB | |
| SCHEMBL4156601 | 0.81 | ATM (0.65) | CTSLCTSBCTSSPOLBALDH1A1 | |
| SCHEMBL2328031 | 0.81 | L3MBTL1 (0.56) | POLBKMT2ACYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232820-A1 | Method for synthesizing oxazinones | WOLFE SAUL (CA) | 2003-12-18 | — | — | US | disclosed |
| WO-2003018565-A1 | METHOD FOR SYNTHESIZING OXAZINONES | CHIROLOGIX PHARMACEUTICALS INC. (CA) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232820-A1 | Method for synthesizing oxazinones | DHPS, HSD17B12, PNPO | CTSL 4677/4885CTSB 4207/4885CTSS 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.